ArticleObesity surgery2026
Comparative Performance of Preoperative Diabetes-Remission Scores Following Metabolic Bariatric Surgery: A Retrospective Cohort Study in a Malaysian Population.
Article in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPreoperative scores predict type 2 diabetes mellitus (T2DM) remission after metabolic bariatric surgery (MBS). The original DiaRem score was refined by adding diabetes duration (DiaRem2), and separately by adding duration together with treatment burden and re-weighted penalties (advanced-DiaRem, Ad-DiaRem). Whether these refinements perform better in Asian, sleeve-predominant populations, and across classes of obesity, is unknown.
methodsWe retrospectively studied patients with T2DM who underwent laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) at a Malaysian tertiary center between 2018 and 2022. DiaRem, DiaRem2 and Ad-DiaRem were calculated from their originally published scoring algorithms. Remission (complete or partial) followed American Society for Metabolic and Bariatric Surgery criteria. The primary analysis comprised patients with clinic-based glycemic follow-up (n = 204); a pre-specified sensitivity analysis additionally included patients followed by telephone (n = 256). Discrimination was compared using DeLong's test.
resultsIn the primary cohort (mean age 43.9 years; 72.1% female; 85.3% LSG), 141 patients (69.1%) achieved remission, declining across DiaRem2 groups (85.0%, 66.7%, 19.4%; trend p < 0.001). Ad-DiaRem discriminated best (area under the curve [AUC] 0.852, 95% CI 0.794-0.904), followed by DiaRem (0.807, 0.732-0.872) and DiaRem2 (0.781, 0.707-0.845). Ad-DiaRem outperformed DiaRem2 (p = 0.009) but not DiaRem (p = 0.115), and DiaRem did not differ from DiaRem2 (p = 0.259). In the larger sensitivity cohort, Ad-DiaRem also outperformed DiaRem (p = 0.036). The ordering held across obesity classes and procedures, with no score-by-procedure interaction.
conclusionIn a predominantly Malay, sleeve-predominant cohort, all three scores predicted remission. Adding diabetes duration alone (DiaRem2) did not improve on the original DiaRem, whereas Ad-DiaRem, which also incorporates treatment burden and re-weighted penalties, discriminated best. Because the medication components were reconstructed retrospectively, and because the study was not powered to detect modest differences between scores, these comparisons require confirmation.
Indexed as
Identifiers
42827212What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.